1st Quarter Financial Results for FYE Mar. 2009 (Consolidated)



July 30, 2008

Exchange where listed: TSE

Name of listed company : TERUMO CORPORATION (URL http://www.terumo.com/)

Company code number : 4543

Representative: : Akira Takahashi, President

Please address all communications to : Shouji Hatano, General Manager, Corporate Communication Dept.

Phone : +81 / 3-3217 -6550 Filing date of 1st quarter financial statements : August 13, 2008

1. Consolidated financial highlights for the interim period ended June 2008 (From April 1, 2008 to June 30, 2008)

(1) Consolidated financial results

(1) Compared Interest 1 opens										
	Net sales		Operating income		Ordinary income		Net income			
	(Millions of yen)	%								
Three months ended June,2008	77,771	-	16,241	-	18,852	-	14,016	-		
Three months ended June, 2007	75,469	17.3	16,986	26.2	18,595	38.2	13,142	63.4		

	Net income per share	Net income per share, fully diluted
	(Yen)	(Yen)
Three months ended June,2008	72.27	-
Three months ended June,2007	66.11	-

(Note) Percentage represent increase (decrease) from the corresponding period in the prior fiscal year.

The amounts shown above ignore values of less than a million yen.

(2) Consolidated financial position

	Total assets	Net assets	Capital asset ratio	Net assets per share	
	(Millions of yen)	(Millions of yen)	%	(Yen)	
June 30, 2008	400,373	301,670	75.3	1,555.06	
March 31, 2008	410,918	288,867	70.3	1,489.10	

(Note) Shareholders' equity: June 30, 2008: 301,570 million yen, March 31, 2008: 288,780 million yen.

The amounts shown above ignore values of less than a million yen.

2. Dividends

	Cash dividends per share				
1st quarter 2nd quarter 3rd quarter 4th quar					total
	(Yen)	(Yen)	(Yen)	(Yen)	
Fiscal year ended March 31,2008	-	14.00	-	18.00	32.00
Fiscal year ending March 31,2009 (forecast)	-	16.00	-	16.00	32.00

(Note) Revise of dividends forecast: None

3. Consolidated forecast for the year ending March 2009 (From April 1, 2008 to March 31, 2009)

	Net sales		Operating inco	me	Ordinary incom	me	Net income		Dividends per share
	(Millions of yen)	%	(Yen)						
Interim year ending September, 2008	155,000	-	34,000	-	34,000	-	22,500	-	116.02
Fiscal year ending March, 2009	318,000	3.8	68,000	1.6	68,000	5.9	45,000	3.7	232.04

(Note) Revise of consolidated forecast: None

Percentage represent increase (decrease) from the corresponding period in the prior fiscal year.

4. Consolidated Financial Statements

(1) Consolidated Balance Sheets

		, -	J - /	
	As of June 3	0, 2008	As of March 3	31, 2008
	Amount	%	Amount	%
(Assets)				
I Current Assets	195,711	48.9%	218,072	53.1%
Cash on hand and in banks	60,649		87,343	
Trade notes/accounts receivable	70,893		69,048	
Merchandise	4,499		3,821	
Finished goods	27,740		25,825	
Raw material	12,332		10,506	
Work in process	6,176		5,735	
Supplies	2,474		2,849	
Deferred income taxes - current	6,306		8,998	
Other current assets	5,466		4,744	
Allowance for doubtful accounts	(828)		(801)	
II Fixed Assets	204,661	51.1%	192,846	46.9%
1. Tangible fixed assets	113,599	28.4%	112,744	27.4%
Buildings and structures	44,140		44,121	
Machinery and transportation equipment	35,212		35,602	
Land	20,440		20,404	
Construction in progress	7,037		6,412	
Other tangible fixed assets	6,768		6,202	
2. Intangible fixed assets	35,908	8.9%	35,125	8.6%
Goodwill	30,811		30,202	
Other intangible fixed assets	5,097		4,922	
3. Investments and other fixed assets	55,152	13.8%	44,976	10.9%
Investments in securities	42,635		$40,\!527$	
Deferred income taxes - noncurrent	5,351		1,878	
Other assets	7,165		2,570	
Total Assets	400,373	100.0%	410,918	100.0%

(Willions of yen,					
	As of June 30	0, 2008	As of March 3	31, 2008	
	Amount	%	Amount	%	
(Liabilities)					
I Current Liabilities	90,857	22.7%	114,457	27.9%	
Trade notes/accounts payable	28,037		27,245		
Short-term bank loans	20,280		35,000		
Accrued income taxes	7,490		17,802		
Reserve for employees bonuses	2,458		4,782		
Reserve for directors bonuses	47		189		
Deferred income taxes - current	197		197		
Notes and accounts payable on equipment	5,320		5,646		
Other current liabilities	27,024		23,593		
II Long-term Liabilities	7,845	2.0%	7,593	1.8%	
Deferred income taxes - noncurrent	43		36		
Reserve for retirement allowance	4,078		4,263		
Reserve for retirement benefits for directors and corporate auditors	728		728		
Other long-term liabilities	2,995		2,565		
Total Liabilities	98,702	24.7%	122,051	29.7%	
(Net Assets)					
I Shareholders' Equity	301,435	75.3%	291,624	71.0%	
Capital stock	38,716		38,716		
Capital surplus	59,030		59,030		
Retained earnings	262,486		252,667		
Treasury stock	(58,798)		(58,790)		
II Evaluation Difference and Foreign Currency Exchange Adjustments	135	0.0%	(2,843)	(0.7%)	
Evaluation difference of investment					
securities	6,653		5,026		
Foreign currency translation adjustments	(6,518)	0.001	(7,869)		
III Minority Interests	100	0.0%	87	0.0%	
Total Net Assets	301,670	75.3%	288,867	70.3%	
Total Liabilities and Net Assets	400,373	100.0%	410,918	100.0%	

(2) Consolidated Statements of Income

(2) Consolidated Statements of Income		(11111)	ions of yen)
	Three months ended June 30, 2008		
	Amo	ount	%
I Net Sales		77,771	100.0%
II Cost of Sales		35,516	45.7%
Gross Profit on Sales		$42,\!255$	54.3%
III Selling, General and Administrative Expenses		26,013	33.4%
Operating Profit		16,241	20.9%
IV Non-operating Income			
Interest income	399		
Dividend income	178		
Royalty income	30		
Exchange gain	2,206		
Equity in profit of affiliated companies	19		
Other non-operating income	224	3,060	3.9%
V Non-operating Expenses			
Interest expenses	97		
Sales discount	141		
Loss on disposal of inventories	18		
Other non-operating expenses	192	449	0.6%
Ordinary Profit		18,852	24.2%
VI Extraordinary Profit			
Gain on sales of fixed assets	0		
Gain on sales of securities	80	81	0.1%
VII Extraordinary Losses			
Loss on disposal of fixed assets	5	5	0.0%
Income Before Taxes		18,927	24.3%
Corporate, Inhabitant and Enterprise Taxes	5,208		
Deferred Taxes (reduction)	(302)	4,906	6.3%
Minority Interest Income (loss) of			
consolidated companies		5	0.0%
Net Income for the Period		14,016	18.0%

3) Co	onsolidated Statements of Cash Flows	(Millions of ye
		Three months ended
		June 30, 2008
		Amount
Ι (Cash Flows from Operating Activities	
1 '	Income Before Taxes	18,927
		· ·
	Depreciation and amortization	4,129
	Amortization of goodwill	512
	Equity in profit of affiliated companies	(19)
	Increase(decrease) in reserve for retirement allowance	(189)
	Increase(decrease) in allowance for doubtful accounts	26
	Increase(decrease) in reserve for directors bonuses	(142)
	Interest and dividend income	(578)
	Interest expenses	97
	Exchange gain (loss)	(230)
	Loss on disposal of fixed assets	5
	Gain on sales of fixed assets	(0)
	Gain on sales of securities	(80)
	Decrease(increase) in trade receivables	177
	Decrease(increase) in inventories	(2,774)
	Increase(decrease) in trade payables	(115)
	Others	(6,720)
,	Sub-total	13,024
	Interest and dividends received	714
	Interest paid	(151)
	Income taxes paid	(16,276)
(Cash Flows from Operating Activities	(2,689)
TT (Cash Flows from Investing Activities	
	Payments for time deposits with maturities	
	exceeding 3 months	(1,490)
	refund of cash in bank	512
	Capital expenditure	(3,560)
	Proceeds from sales of tangible fixed assets	(5,500)
	_	<u> </u>
	Payments for acquisition of intangible fixed assets	(305)
	Acquisition of investment in securities	0
	Proceeds from sale of marketable securities	580
	Expense relating to acquisition of newly consolidated subsidiary	(3,286)
(Cash Flows from Investing Activities	(7,548)
		(1,020)
11 (Cash Flows from financing Activities	(1 × 000)
	Increase(decrease) in short-term bank loan	(15,000)
	Buyback of treasury stock	(7)
	Dividends paid	(3,490)
	Cash Flows from Financing Activities	(18,498)
	Effect of Exchange Rate Changes on Cash and	1,064
	Cash Equivalents Change in Cash and Cash Equivalents	(27,671)
, ,	onango in oasii ana oasii rquivaiciiis	(41,011)
	Cash and Cash Equivalents at Beginning of Period	85,377

5. Segment Information

(1) Business Segments

(Millions of yen)

	Three months ended June 30, 2008			
	Amo	unt		
	G-1	Operating		
	Sales	income		
General hospital products	37,200	8,275		
Cardiac & Vascular products	33,108	9,801		
Blood transfusion products	6,232	1,067		
Consumer Home Health Care products	1,230	42		
Corporate expenses	-	(2,945)		
Total	77,771	16,241		

(Note) Main products belonging to each product segment

Product segment	Main products
General hospital products	
Disposable medical devices and Medical electronics	Syringe, Needle, Solution Administration set, I.V.catheter, Blood collection tube, Electronic medical equipment, etc.
Pharmaceuticals	I.V.solutions, Prefilled syringe, Nutritional products, etc.
CAPD products	Dialysis solution, etc.
Diabetes care products (Hospital)	Blood glucose monitor, etc.
Home parenteral nutrition and oxygen	Home infusion systems, Home oxygen systems, etc.
Cardiac & Vascular products	
Interventional systems	PTCA catheters, Coronary stent, Guide wires, Angiographic catheters, Cerebral aneurysm coils, etc.
Cardiovascular systems	Roller pump, Oxygenarators, Blood tubing set, etc.
Vascular grafts	Artificial vascular grafts
Blood transfusion products	Blood bags, Blood transfusion administration set, Medical electronic equipment for blood collection, etc.
Consumer Health Care Products	Digital Thermometers, Blood pressure monitor, etc.

(2) Geographic segments

(Millions of yen)

	Three months ended June 30, 2008 Amount				
	Operating				
	Sales	income			
Japan	39,924	14,015			
Europe	15,987	2,440			
Americas	13,943	837			
Asia and others	7,916	1,916			
Corporate expenses	-	(2,969)			
Total	77,771	16,241			

(3) Sales results by regions

(Millions of ven)

		(Millions of yell)
	Three months ended	
	June 30, 2008	
	Amount	%
Japan	39,912	51.3%
Europe	15,987	20.6%
Americas	13,943	17.9%
Asia and others	7,928	10.2%
Total	77,771	100.0%

(Note) Sales in 'Asia and others' includes direct sales from Japan.

Reference information: Consolidated Financial Statements of the previous year

1. Consolidated Statements of Income

(Millions of yen)

	Three months ended June 30, 2007	
	Amount	%
Net sales	75,469	100.0%
Cost of sales	33,964	45.0%
Gross profit	41,504	55.0%
Selling, general and administrative expenses	24,518	32.5%
Operating income	16,986	22.5%
Non-operating income / expenses	1,609	
Ordinary income	18,595	24.6%
Extraordinary income / expenses	1,040	
Income before taxes	19,636	26.0%
Corporate, inhabitant and enterprise taxes	6,480	
Minority interests	12	
Net income for the period	13,142	17.4%

2. Consolidated Statements of Cash Flows

	(Initiality of July	
	Three months ended	
	June 30, 2007	
Cash flows from operating activities	11,990	
Cash flows from investing activities	(8,107)	
Cash flows from financing activities	(3,188)	
Effect of exchange rate changes on cash and cash equivalents	637	
Change in cash and cash equivalents	1,331	
Cash and cash equivalents at beginning of period	43,049	
Cash and cash equivalents at end of period	44,380	

3. Segment Information

(1) Sales results by product segments

(Millions of yen)

	Three months ended June 30, 2007	
	Amount	%
Disposable medical equipments	20,691	27.4%
Pharmaceuticals	10,175	13.5%
Blood transfusion systems	5,850	7.8%
General hospital products	36,716	48.7%
Catheter systems	19,108	25.3%
Cardiovascular systems	9,601	12.7%
Vascular grafts	2,514	3.3%
Cardiac & vascular products	31,224	41.3%
CAPD systems	1,769	2.3%
Diabetes care products	3,454	4.6%
Other products	2,304	3.1%
Home health care products	7,528	10.0%
Total	75,469	100.0%

(Note) Main products belonging to each product segment

Product segment	Main products	
Disposable medical equipment	Syringes, Needles, Solution Administration sets, I.V.catheters,	
	Blood collection tubes, Electronic medical devices, etc.	
Pharmaceuticals	I.V.solution, Prefilled syringes, Nutritional products, etc.	
Blood transfusion systems	Blood bags, Blood transfusion administration sets, medical	
	electronic devices for blood collection, etc.	
Catheter systems	PTCA dilation catheters, Coronary stents, Guide wires,	
	Angiographic catheters, Cerebral aneurysm coils, etc.	
Cardiovascular systems	Roller pumps, Hollow fiber oxygenators, Blood circuits, etc.	
Vascular grafts	Artificial vascular grafts	
CAPD systems	Dialysis solution, etc.	
Diabetes care products	Blood glucose monitors, etc.	
Other products	Home oxygen systems, Home nutritional products, Digital	
	Thermometers, Electronic sphygmomanometers, etc.	

(2) Sales results by region

	Three months	Three months ended June 30, 2007	
	June 30, 2		
	Amount	%	
Japan	39,108	51.8%	
Europe	14,271	18.9%	
America	14,508	19.2%	
Asia and Others	7,582	10.1%	
Total	75,469	100.0%	